Innovative Research & Development

Teva's proprietary research and development pipeline is currently focused primarily on three niche specialty areas: neurological disorders, autoimmune diseases and oncology. One element of Teva's approach to innovative product development is to leverage the advantages arising from Teva's status as the world's leading generic company, such as its relationships with health insurers and the trade. These efforts culminated in 2 innovative products introduction into global markets : Copaxone® (glatiramer acetate) for MS and Azilect® for Parkinson's disease (PD).

In building its pipeline, Teva focuses on products with meaningful differentiation from existing products in terms of clinical attributes and expected economic value and benefit to patients and health insurers. In addition, different new technologies are incorporated early in the development process to reduce the risk at more advanced stages of R&D (e.g., biomarkers). Teva's Innovative Ventures unit focuses on early identification and evaluation of potential proprietary compounds, primarily in the above niche specialty areas. Teva invests in companies with promising products and technologies, under terms providing Teva, in most cases, with strategic rights and other options, thereby allowing Teva to simultaneously explore selected new products and technologies while limiting its financial exposure. At the drug discovery phase, Teva leverages, among other things, its relationships with the Israeli academic community and start-up companies to gain early access to potential projects. In 2008, Teva initiated a more active global sourcing process for selected indications within the therapeutic areas of neurology, autoimmune diseases and oncology.

TEVA Partners

Your Partner in Specialty Product Development
At Teva, we built our successful reputation on the development, production and marketing of generic and proprietary branded pharmaceuticals and active pharmaceutical ingredients.

With the launch of Teva Partners, we're placing new emphasis on bringing specialty products to market. Through partnerships, we offer smaller companies and academic institutions access to resources that include:

Proven Success - We're building on our successes in developing proprietary therapies such as the blockbuster COPAXONE® and AZILECT® - the rights to both of which were acquired from renowned institutions.
Genuine Commitment - We are highly selective about the projects that pass our approval process.
Projects that are selected for partnering receive our concentrated effort.
Reliance on External Research & Partnering - We strive to become a partner of choice as Teva's Innovative business depends primarily on in-licensing and partnering to obtain products for development.
Unmatched Deal Flexibility - The structure and terms for each deal are negotiated to create a win-win situation for both Teva and our partners.

More ...